Merck and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Merck and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
CPHI Milan introduces new specialist zones
The event runs from 6-8 October 2026 at the Fiera Milano exhibition centre in Rho, Italy
Latest content
NRG Therapeutics appoints Claus Sundgreen as Chief Medical Officer
Sundgreen previously held senior medical leadership positions across biotechnology and pharmaceutical companies
Read More
Richmond Pharmacology appoints Adam Hurd as Operations Director
Hurd previously spent almost twenty years working within the NHS
Read More
CNX Therapeutics appoints Lucy Ralph as Chief People and Transformation Officer
Ralph previously held senior leadership roles at Norstella and Evaluate
Read More
Healthcare Communications Association appoints Emma Kenny as new interim CEO
Mike Dixon, the current CEO, is retiring after holding the role for nine years
Read More
Intelligence
Leading through complexity
Strengthening strategic judgement during uncertainty – exploring the strategic concepts that matter most
Read More
The Amazon reckoning: GLP-1s and the consumer lifestyle shift – why the molecule is no longer enough
Amazon’s entry into the GLP-1 market should be a signal to pharma that it needs to shift focus from molecule to ‘Operating Model’
Read More
Lupus – moving patient care beyond current therapies towards resetting the immune system
Precision medicine is no longer theoretical, but increasingly achievable for people living with lupus
Read More
Forging a connection through creativity
A spark of creativity can cut through complexity, adding real value and helping to forge true connections with patients
Read More
The UK’s life sciences’ crossroads: competing in a market defined by speed, scale and investment
The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates
Read More
Launching into an AI-powered future: a prescription for success
Making launch more effective, precise, cost-effective and agile demands new thinking and new technologies
Read More
Blogs
Latest
The Future of Decisioning
August 20, 2026 | Havas Lynx|Havas Lynx, Point.1
The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of …
Lucid Group Names Eric Muller as Chief Executive Officer to Lead Next Phase of Growth
August 19, 2026 | Lucid Group Communications Limited|
Rick Sannem, outgoing CEO, transitions to Strategic Advisor to the Board
Treating phase 2 study design as a scientific decision is compromising launch performance, warns expert
August 17, 2026 | Nmblr|
17th August 2026 – Treating Phase 2 study design solely as a set of scientific decisions, without commercial input, is compromising launch performance, according to …
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
August 11, 2026 | Genesis Research Group|HEOR, Market Access, Pharma, RWE, biotech, genesis, pharmaceutical
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead …
Why Modern Dermatology Demands Curiosity Over Precision
August 5, 2026 | Medscape Education|
In the high-stakes world of healthcare research and product development, success has long been measured by rigid definitions of precision and predictable trajectories. However, as …
Permission to pause: making treatment breaks part of the cancer care conversation
August 5, 2026 | Cuttsy + Cuttsy|Cancer, Social Listening, Treatment breaks, Treatment pause, oncology
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
July 24, 2026 | Cuttsy + Cuttsy|EU HTA, Patient involvement, clinical trials, design
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at …
Infographic: Are data blind spots putting your launch at risk?
July 16, 2026 | Inizio|AI, Pharma, Product Launch, healthcare
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult …
Why faster trials make participant understanding more important than ever
July 15, 2026 | Cuttsy + Cuttsy|Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.